C12N 2760/18571
Demonstrated in vivo effect
C12N2760/18571 (Demonstrated in vivo effect) appears on 84 US grants and 128 published applications in this corpus.
Search patents in C12N- Granted patents
- 84
- Published applications
- 128
- Assignees
- 69
- Inventors
- 229
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2009 | 0 | 1 |
| 2010 | 0 | 1 |
| 2011 | 0 | 3 |
| 2012 | 0 | 0 |
| 2013 | 0 | 3 |
| 2014 | 1 | 7 |
| 2015 | 6 | 8 |
| 2016 | 4 | 8 |
| 2017 | 8 | 9 |
| 2018 | 6 | 4 |
| 2019 | 8 | 19 |
| 2020 | 10 | 10 |
| 2021 | 7 | 11 |
| 2022 | 10 | 12 |
| 2023 | 7 | 14 |
| 2024 | 7 | 7 |
| 2025 | 7 | 7 |
| 2026 | 3 | 4 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Conformationally stabilized RSV pre-fusion F proteins11 Aug 2026US 12,703,721 B2
- Recombinant human/bovine parainfluenza virus 3 (B/HPIV3) expressing a chimeric RSV/PIV3 F protein and uses thereof2 Jun 2026US 12,643,925 B2The U.S.A., as represented by the Secretary, Department of Health and Human Services
- Methods for inactivating and storing respiratory syncytial virus14 Apr 2026US 12,600,750 B2Xiamen Innovax Biotech Co., Ltd.
- Antigenic multimeric respiratory syncytial virus polypeptides28 Oct 2025US 12,454,553 B2Sanofi
- Methods for immunizing pre-immune subjects against respiratory syncytial virus (RSV)14 Oct 2025US 12,440,552 B2University of Massachusetts
- Antigenic Multimeric Respiratory Syncytial Virus Polypeptides10 Sep 2026US 2026/0265309 A1Sanofi
- Truncated respiratory syncytial virus f protein and use thereof28 May 2026US 2026/0144858 A1Xiamen Innovax Biotech Co., Ltd.
- Method of vaccination with an attenuated rsv vaccine formulation2 Apr 2026US 2026/0091105 A1The United States of America, as represented by the Secretary, Department of Health and Human Services
- Adenoviral vector vaccine against respiratory syncytial virus, and preparation method therefor and use thereof1 Jan 2026US 2026/0000746 A1Cansino Biologics Inc.
- Rsv vaccine as well as preparation method thereof and use thereof25 Dec 2025US 2025/0387465 A1Beijing Genevax Biotechnology Co., Ltd.
Most cited
By later US patents
- Vaccination in newborns and infants79US 9,623,095 B2CureVac AG · 2017
- Vaccination in newborns and infants35US 10,172,935 B2CureVac AG · 2019
- Polymeric carrier cargo complex for use as an immunostimulating agent or as an adjuvant33US 11,110,166 B2CureVac AG · 2021
- Vaccination in newborns and infants32US 10,596,252 B2CureVac AG · 2020
- Vaccination in newborns and infants32US 10,729,761 B2CureVac AG · 2020